Troponin-only Manchester Acute Coronary Syndromes (T-MACS) decision aid: single biomarker re-derivation and external validation in three cohorts

Conclusions T-MACS could ‘rule out’ ACS in 40% of patients, while ‘ruling in’ 5% at highest risk using a single hs-cTnT measurement on arrival. As a clinical decision aid, T-MACS could therefore help to conserve healthcare resources.
Source: Emergency Medicine Journal - Category: Emergency Medicine Authors: Tags: Open access, Editor's choice, Drugs: cardiovascular system, Acute coronary syndromes Original article Source Type: research